Dashboard
Manage Tickers

VXRTVaxart, Inc.

Nasdaq vaxart.com


$ 0.94 $ -0.05 (-4.78 %)    

Monday, 16-Sep-2024 15:59:46 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 473.14 $ -2.10 (-0.44 %)
DIA $ 417.33 $ 2.44 (0.59 %)
SPY $ 562.48 $ 0.83 (0.15 %)
TLT $ 101.29 $ 0.92 (0.92 %)
GLD $ 238.61 $ -0.02 (-0.01 %)
$ 0.9399
$ 0.99
$ 0.84 x 400
-- x --
$ 0.94 - $ 1.07
$ 0.52 - $ 1.54
3,375,168
na
213.77M
$ -0.94
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-08-2024 06-30-2024 10-Q
2 05-13-2024 03-31-2024 10-Q
3 03-14-2024 12-31-2023 10-K
4 11-02-2023 09-30-2023 10-Q
5 08-03-2023 06-30-2023 10-Q
6 05-04-2023 03-31-2023 10-Q
7 03-15-2023 12-31-2022 10-K
8 11-09-2022 09-30-2022 10-Q
9 08-08-2022 06-30-2022 10-Q
10 05-09-2022 03-31-2022 10-Q
11 02-24-2022 12-31-2021 10-K
12 11-04-2021 09-30-2021 10-Q
13 08-05-2021 06-30-2021 10-Q
14 05-06-2021 03-31-2021 10-Q
15 02-25-2021 12-31-2020 10-K
16 11-12-2020 09-30-2020 10-Q
17 08-06-2020 06-30-2020 10-Q
18 05-12-2020 03-31-2020 10-Q
19 03-19-2020 12-31-2019 10-K
20 11-12-2019 09-30-2019 10-Q
21 08-08-2019 06-30-2019 10-Q
22 05-09-2019 03-31-2019 10-Q
23 02-06-2019 12-31-2018 10-K
24 11-13-2018 09-30-2018 10-Q
25 08-10-2018 06-30-2018 10-Q
26 05-15-2018 03-31-2018 10-Q
27 02-06-2018 12-31-2017 10-Q
28 11-07-2017 09-30-2017 10-Q
29 09-01-2017 06-30-2017 10-K
30 05-08-2017 05-02-2017 10-Q
31 02-06-2017 12-31-2016 10-Q
32 11-08-2016 09-30-2016 10-Q
33 09-13-2016 06-30-2016 10-K
34 05-10-2016 03-31-2016 10-Q
35 02-08-2016 12-31-2015 10-Q
36 11-06-2015 09-30-2015 10-Q
37 09-11-2015 06-30-2015 10-K
38 05-08-2015 03-31-2015 10-Q
39 02-06-2015 12-31-2014 10-Q
40 11-07-2014 09-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

vaxart-announces-preclinical-data-showing-its-mucosal-vaccine-technology-stimulates-immune-response-against-hpv-related-tumors-reduces-tumor-size-and-increases-survival-in-animal-model-indicating-potential-for-non-invasive-treatment-of-hpv-related-cervical-dysplasia
Vaxart Announces Preclinical Data Showing ...
08/28/2024 12:04:41

oral-vaccine-focused-penny-stock-vaxart-is-uniquely-positioned-analyst-sees-almost-83-upside
Oral Vaccine Focused Penny Stock Vaxart Is...
08/15/2024 17:57:40

Oppenheimer initiates Vaxart coverage with an Outperform rating and $4 price target, citing a bullish outlook on its oral vacci...

oppenheimer-initiates-coverage-on-vaxart-with-outperform-rating-announces-price-target-of-4
Oppenheimer Initiates Coverage On Vaxart w...
08/15/2024 09:31:20

Oppenheimer initiates coverage on Vaxart (NASDAQ:VXRT) with a Outperform rating and announces Price Target of $4.

1m-bet-on-this-penny-stock-check-out-these-4-stocks-under-2-insiders-are-aggressively-buying
$1M Bet On This Penny Stock? Check Out The...
06/21/2024 12:22:05

12-health-care-stocks-moving-in-wednesdays-intraday-session
12 Health Care Stocks Moving In Wednesday'...
06/19/2024 16:30:59

12-health-care-stocks-moving-in-tuesdays-intraday-session
12 Health Care Stocks Moving In Tuesday's ...
06/18/2024 16:31:11

vaxart-stock-is-moving-higher-after-the-bell-whats-going-on
Vaxart Stock Is Moving Higher After The Be...
06/17/2024 20:32:16

Vaxart, a clinical-stage biotechnology company developing a range of oral recombinant vaccines, announced Monday that proceeds ...

vaxart-provides-business-update-expects-net-proceeds-from-40m-offering-and-reimbursment-under-project-nextgen-award-of-up-to-453m-to-extend-cash-runaway-into-2026
Vaxart Provides Business Update; Expects N...
06/17/2024 20:08:10

— Cash runway extended into 2026 — — Received one of the largest BARDA-funded Project NextGen Awards to date, up to $453 millio...

vaxart-bags-453m-worth-barda-funded-project-seeks-to-raise-40m-via-equity-offering
Vaxart Bags $453M Worth BARDA-Funded Proje...
06/14/2024 14:06:12

Vaxart (VXRT) shares surged 23% in premarket session after receiving a $453 million project award from BARDA to conduct a COVID...

why-adobe-shares-are-trading-higher-by-around-15-here-are-20-stocks-moving-premarket
Why Adobe Shares Are Trading Higher By Aro...
06/14/2024 12:19:25

vaxart-shares-are-trading-higher-after-the-company-received-a-barda-funded-project-nextgen-award-valued-up-to-453-million-to-conduct-a-phase-2b-study-evaluating-its-covid-19-oral-pill-vaccine-candidate
Vaxart shares are trading higher after the...
06/14/2024 11:24:47

reported-earlier-vaxart-launches-40m-underwritten-offering-of-50m-common-stock-at-080share
Reported Earlier, Vaxart Launches $40M Und...
06/14/2024 06:50:03

Gross proceeds to Vaxart from the offering are expected to be $40 million, before deducting underwriting discounts and commissi...

12-health-care-stocks-moving-in-thursdays-after-market-session
12 Health Care Stocks Moving In Thursday's...
06/13/2024 20:31:04

vaxart-receives-up-to-453m-award-from-barda-for-phase-2b-study-of-oral-covid-19-vaccine
Vaxart Receives Up To $453M Award From BAR...
06/13/2024 20:16:20

Initial $65.7M For Study Start-Up; Remaining $387.2M Pending Further Study Approval; Enrollment Expected Summer 2024, Interim A...

palo-alto-networks-shares-drop-after-q3-results-in-line-guidance-the-details
Palo Alto Networks Shares Drop After Q3 Re...
05/20/2024 20:20:02

Palo Alto Networks reported quarterly earnings of $1.32 per share which beat the analyst consensus estimate of $1.25 by 5.6%. Q...

12-health-care-stocks-moving-in-tuesdays-pre-market-session
12 Health Care Stocks Moving In Tuesday's ...
05/14/2024 12:06:42

12-health-care-stocks-moving-in-mondays-after-market-session
12 Health Care Stocks Moving In Monday's A...
05/13/2024 20:31:07

vaxart-stock-climbs-after-blockbuster-q1-revenue
Vaxart Stock Climbs After Blockbuster Q1 R...
05/13/2024 20:29:57

Vaxart reported quarterly losses of 14 cents per share, inline with the analyst consensus estimate. Quarterly sales clocked in ...

vaxart-to-meet-with-fda-in-mid-2024-to-evaluate-clinical-data-and-discuss-next-steps-for-its-norovirus-program-anticipates-cash-runway-into-late-q4-of-2024
Vaxart To Meet With FDA In Mid-2024 To Eva...
05/13/2024 20:14:22

These data will inform potential next steps, such as potentially conducting a Phase 2b study and potentially a GII.4 challenge ...

vaxart-q1-2024-gaap-eps-014-inline-sales-2181m-beat-800000k-estimate
Vaxart Q1 2024 GAAP EPS $(0.14), Inline, S...
05/13/2024 20:11:16

Vaxart (NASDAQ:VXRT) reported quarterly losses of $(0.14) per share which met the analyst consensus estimate. The company repo...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION